SCHEMBL10106334

SCHEMBL10106334

Cc1cccc(C(c2cc(C=O)ccc2O)c2cc(C=O)ccc2O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
PTGS2 P35354 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 4/20 0.41
ALDH5A1 P51649 2/20 0.41
ABAT P80404 2/20 0.41
HPGD P15428 2/20 0.41
TRIM24 O15164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
ACP3 P15309 1/20 0.38
AOX1 Q06278 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
CYP2A6 P11509 1/20 0.35
LMNA P02545 1/20 0.35
ESR1 P03372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106319 0.85 ALDH1A1 (0.45) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106351 0.84 ALDH1A1 (0.51) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL7074379 0.83 KDM4E (0.50) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106344 0.82 RAB9A (0.43) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106385 0.82 ALDH1A1 (0.44) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106338 0.82 ALDH1A1 (0.48) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106450 0.82 ALDH1A1 (0.40) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10106416 0.82 KDM4E (0.40) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL10119404 0.81 PTGS2 (0.39) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL17557781 0.80 CYP2A6 (0.47) KDM4EPTGS2RAB9AALDH1A1ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML KDM4E 4428/4885PTGS2 935/4885RAB9A 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.